论文部分内容阅读
第59届美国心脏学会年会上公布了一项RE-LY研究的亚组分析结果,无论患者处于何种卒中风险,与目前的标准治疗华法林相比,达比加群酯均能进一步降低房颤患者
A subgroup analysis of the RE-LY study was published at the 59th Annual Meeting of the American Heart Association to show that dabigatran etexilate could be further reduced compared to current standard-warfarin treatment regardless of stroke risk Atrial fibrillation patients